Search results
Jun 8, 2017 · Being vaccinated against HPV types 16 and 18 significantly reduces the risk of developing cervical cancer. HPV vaccination is the most cost-effective public health measure against cervical cancer. The Global Strategy to accelerate the elimination of cervical cancer as a public health problem recommends vaccination for girls before the age of 15.
The 9-valent HPV vaccine protects against HPV types 16 and 18, which cause about 66% of cervical cancers and most other HPV-attributable cancers in the United States, and five additional cancer-causing types, which account for about 15% of cervical cancers. It also protects against HPV 6 and 11, which cause most anogenital warts.
CERVICAL CANCER VACCINES, COSTS AND AGE GROUPS. The most well-known vaccine is Gardasil 9, which offers protection against nine types of HPV that are responsible for a majority of HPV-related cancers.
The cervical cancer vaccine price in India is affordable and therefore women don’t need to worry regarding the pricing. Most of the cervical cancer vaccine costs vary in the range of 2000 INR to 4000 INR depending on the vaccine brand and manufacturer. Q7.
Feb 5, 2024 · "Our government will encourage vaccination for girls in the age group of 9-14 years to prevent cervical cancer," Sitharaman said while presenting the interim budget 2024 in the Lok Sabha. Sitharaman emphasised the government's plans to set up more medical colleges and said that the government aims to serve the people through improved healthcare services.
Sep 1, 2022 · According to the officials, the qHPV vaccine CERVAVAC has demonstrated robust antibody response that is nearly 1,000 times higher than the baseline against all targeted HPV types and in all dose and age groups. Cervical cancer in India ranks as the second most frequent cancer among women between 15 and 44 years of age.
Aug 2, 2023 · Two retrospective cohort studies evaluated HPV vaccine effectiveness against cervical cancer utilizing national population health registries (Table 1). 13, 14 In Denmark, Kjaer et al. found that the vaccine was effective against cervical cancer among those who initiated the vaccine series prior to age 17 (aIRR = 0.14; 95% CI = 0.04, 0.53), adjusting for age, education, and ethnicity (Table 2, Figure 5). In Sweden, Lei et al. found that the vaccine was statistically significantly effective ...
